Chemomab Therapeutics Ltd.
Business
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing therapeutics that target inflammation and fibrosis. Its main product candidate is nebokitug, a first-in-class humanized monoclonal antibody designed to bind and neutralize the chemokine CCL24 to provide dual anti‑fibrotic and anti‑inflammatory activity. Key business activities include preclinical research, clinical development programs (notably Phase 2/Phase 3 planning in primary sclerosing cholangitis and a Phase 2‑ready program in systemic sclerosis), intellectual property management and outsourced manufacturing. The company conducts global clinical trials and academic collaborations and plans to commercialize its products either alone or via partnerships, distribution or licensing arrangements across major markets including the United States, European Union and Japan.
Summary from filing dated 2025-04-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 17 | 6 | 5 | 13 | 8 | |
| General and administrative | 12 | 6 | 1 | 6 | 6 | |
| Total operating expenses | 29 | 12 | 6 | 23 | 13 | |
| Financing (income) expenses, net | −353,000 | 111,000 | — | — | — | |
| Loss before taxes | 28 | 12 | — | 27 | 13 | |
| Taxes on income (benefit) | −534,000 | 0 | — | — | 306,000 | |
| Net loss for the year | 28 | 12 | 6 | 27 | −14 | |
| Basic loss per Ordinary Share | 0.12 | 0.06 | — | — | — | |
| Diluted loss per Ordinary Share | 0.12 | 0.06 | — | — | — | |
| Weighted average number of Ordinary Shares outstanding, basic | 228 | 207 | — | — | — | |
| Weighted average number of Ordinary Shares outstanding, diluted | 228 | 207 | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 14 | 15 | 12 | 18 | 8 | |
| Short-term bank deposit | 26 | 46 | 24,000 | — | — | |
| Restricted cash | 77,000 | 0 | — | — | — | |
| Other receivables and prepaid expenses | 2 | 2 | 141,000 | 636,000 | — | |
| Total current assets | 42 | 63 | 12 | 18 | 11 | |
| Restricted cash | 0 | 55,000 | 53,000 | — | — | |
| Long-term prepaid expenses | 733,000 | 908,000 | — | 57,000 | 1 | |
| Property and equipment, net | 367,000 | 357,000 | 152,000 | 158,000 | 385,000 | |
| Operating lease right-of-use assets | 227,000 | 345,000 | 428,000 | 1 | 2 | |
| Total non-current assets | 1 | 2 | 637,000 | 2 | 2 | |
| Total assets | 43 | 64 | 12 | 20 | 13 | |
| Trade payables | 2 | 1 | 93,000 | 875,000 | 396,000 | |
| Accrued expenses | 3 | 555,000 | 715,000 | — | — | |
| Employee and related expenses | 2 | 653,000 | 438,000 | — | — | |
| Operating lease liabilities | 123,000 | 106,000 | 70,000 | 391,000 | 2 | |
| Total current liabilities | 7 | 3 | 1 | 4 | 3 | |
| Non-current operating lease liabilities | 91,000 | 237,000 | 358,000 | 725,000 | — | |
| Total non-current liabilities | 91,000 | 237,000 | 358,000 | 725,000 | 210,000 | |
| Commitments and contingent liabilities | — | — | — | — | — | |
| Total liabilities | 7 | 3 | 2 | 5 | 3 | |
| Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021 | 0 | 0 | — | — | — | |
| Treasury share at cost (11,640,460 shares as of December 31, 2022) | −1 | 0 | — | — | — | |
| Additional paid-in capital | 101 | 98 | 34 | 119 | 87 | |
| Accumulated deficit | −64 | −36 | −24 | −105 | −78 | |
| Total shareholders' equity | 36 | 61 | 11 | 12 | 10 | |
| Total liabilities and shareholders' equity | 43 | 64 | 12 | 20 | 13 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Net loss for the year | −28 | −12 | −6 | −27 | −14 | |
| Depreciation | 58,000 | 34,000 | 24,000 | 281,000 | 66,000 | |
| Share-based compensation | 3 | 2 | 130,000 | 1 | 2 | |
| Change in other receivables and prepaid expenses | −64,000 | −2 | −99,000 | 2 | — | |
| Change in trade payables | 352,000 | 1 | 68,000 | 1 | 287,000 | |
| Change in accrued expenses | 3 | −1 | 392,000 | — | — | |
| Change in employees and related expenses | 907,000 | 215,000 | 194,000 | −347,000 | 528,000 | |
| Change in operating leases | −11,000 | −2,000 | — | — | — | |
| Net cash used in operating activities | −20 | −12 | −5 | −16 | −14 | |
| Investment in deposits | 20 | −46 | −24,000 | — | — | |
| Long-term lease deposit | 0 | 4,000 | — | — | — | |
| Sale of asset held for sale | 0 | 1 | — | — | — | |
| Purchase of property and equipment | −68,000 | −239,000 | −38,000 | −95,000 | 213,000 | |
| Net cash provided by (used in) investing activities | 20 | −45 | −62,000 | −95,000 | −213,000 | |
| Cash acquired in Merger | 0 | 2 | — | — | — | |
| Exercise of options | 143,000 | 10,000 | — | — | — | |
| Treasury share at cost | −1 | 0 | — | — | — | |
| Issuance of shares and warrants, net of issuance costs | 267,000 | 59 | 4 | — | — | |
| Net cash provided by (used in) financing activities | −808,000 | 61 | 5 | 27 | 21 | |
| Change in cash, cash equivalents and restricted cash | −2 | 4 | −554,000 | 10 | 6 | |
| Income taxes received | 351,000 | 0 | — | — | — | |
| Income taxes paid | −5,000 | 0 | 84,000 | 161,000 | 244,000 | |
| Interest received | 972,000 | 74,000 | — | — | — | |
| Right-of-use asset recognized with corresponding lease liability | 17,000 | 345,000 | 233,000 | — | — | |
| Liabilities assumed, net of non-cash assets received in Merger | 0 | 49,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Chemomab Therapeutics Ltd.'s CIK number?
Chemomab Therapeutics Ltd.'s SEC CIK number is 0001534248 (1534248). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Chemomab Therapeutics Ltd.'s SEC filings?
All of Chemomab Therapeutics Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Chemomab Therapeutics Ltd. last report earnings?
Chemomab Therapeutics Ltd. (CMMB) most recently filed an earnings 8-K with the SEC on May 11, 2023, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001178913-23-001809). This is Chemomab Therapeutics Ltd.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Chemomab Therapeutics Ltd.'s most recent earnings 8-K?
Chemomab Therapeutics Ltd.'s latest earnings 8-K (Item 2.02) was filed May 11, 2023 under accession 0001178913-23-001809. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Chemomab Therapeutics Ltd.'s latest earnings 8-K →
Look up any company's CIK number →